

# Effects on the microbiome during treatment of a staphylococcal device infection

Andre Mu  
Daniel McDonald  
Alan K. Jarmusch  
Cameron Martino  
Caitriona Brennan  
MacKenzie Bryant  
Gregory C. Humphrey  
Julia Toronczak  
Tara Schwartz  
Dominic Nguyen  
Gail Ackermann  
Anthony D'Onofrio  
Steffanie A. Strathdee  
Robert T. Schooley  
Pieter C. Dorrestein  
Rob Knight  
Saima Aslam

---

## Video Byte

**Keywords:** bacteriophages, phage therapy, microbiome, metabolomics, Staphylococcus aureus, bacteria, phage, infection

**Posted Date:** October 14th, 2021

**DOI:** <https://doi.org/10.21203/rs.3.rs-969336/v1>

**License:**  This work is licensed under a Creative Commons Attribution 4.0 International License.

[Read Full License](#)

---

# Abstract

*Staphylococcus aureus* is a common commensal that can cause an array of serious human diseases, from mild skin infection to life-threatening disease. *S. aureus* can rapidly adapt to selective pressures such as antibiotics, and this ability is enhanced by biofilm formation on implanted medical devices. With antibiotic resistance on the rise, there is a growing need to find non-antibiotic alternatives to treat serious infections. One such alternative is bacteriophage therapy, which introduces viruses that selectively infect and kill bacteria. A recent study sought to better understand the impact of bacteriophage therapy on the host microbiome. In a follow-up to a case study of a patient with an implanted cardiac device who was treated with bacteriophage therapy combined with antibiotics for a persistent *S. aureus* infection, researchers used high-throughput sequencing to evaluate patient microbial samples from the gut, saliva, and skin. They found that the microbiota profile of the patient remained largely unchanged throughout treatment. Metabolomic analyses suggested potential indirect effects on the host skin microbiome, and genomes from the bacteriophages used for treatment were not detected in the saliva, stool, or skin samples, while they were present in patient serum. While further studies are needed to expand upon the results of this case study, the data support the use of bacteriophages as a non-antibiotic method of treating bacterial infections without affecting the overall host microbiome.